$RGBP up 8.80% @.0816 as Early data suggests molecules are stable and may be delivered orally Regen BioPharma, Inc. Begins In Vivo Assessment of Small Molecule Agonists to NR2F6 Nuclear Receptor https://finance.yahoo.com/news/regen-biopharma-inc-begins-vivo-232600694.html?soc_src=social-sh&soc_trk=tw via @YahooFinance